Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axogen, Inc.AXGN · Entity 4297 | Director | August 11, 2026 | August 12, 2026 |
| BAXTER INTERNATIONAL INCBAX · Entity 1707 | Director | May 05, 2026 | May 07, 2026 |
| ChronoScale Holdings CorpEKSO · Entity 4331 | Director | September 14, 2017 | September 15, 2017 |
| Solventum CorpSOLV · Entity 1645 | Director | May 15, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axogen, Inc.
Report date August 11, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 107,976 |
Ending reported balance
After 2026-08-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-11 · Exercise / conversion · Acquired 13,353 · Balance 121,329 Row 2 · 2026-08-11 · Sale · Disposed 13,353 · Balance 107,976 F1: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2026. F2: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $47.82 to $49.02 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| Employee Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $14.85 · Expires 2027-06-01 | Direct | 0 |
Reported balance
After 2026-08-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-11 · Exercise / conversion · Disposed 13,353 · Balance 0 F3: All shares of Axogen, Inc. common stock underlying the board of director's stock option were fully vested on May 14, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2026.
F2: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $47.82 to $49.02 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3: All shares of Axogen, Inc. common stock underlying the board of director's stock option were fully vested on May 14, 2018.
BAXTER INTERNATIONAL INC
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $1 par valueSEC Table I · non-derivative | Direct | 44,235 |
Reported balance
After 2026-05-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-05 · Grant · Acquired 12,836 · Balance 44,235 F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. F2: Total includes the automatic reinvestment of dividends. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.
F2: Total includes the automatic reinvestment of dividends.
ChronoScale Holdings Corp
Report date September 14, 2017 · Filed September 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,264 |
Reported balance
After 2017-09-14 transaction · row 1
1 source rowRow 1 · 2017-09-14 · Purchase · Acquired 16,264 · Balance 16,264 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.22 to $1.24, inclusive. The reporting person undertakes to provide to Ekso Bionics Holdings, Inc., any security holder of Ekso Bionics Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.22 to $1.24, inclusive. The reporting person undertakes to provide to Ekso Bionics Holdings, Inc., any security holder of Ekso Bionics Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
Solventum Corp
Report date May 15, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,300 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 3,300 · Balance 3,300 F1: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F2: The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.
F2: The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
HOLOGIC INC
Report date April 07, 2026 · Filed April 09, 2026
Section 16 reporting ended · disclosed 2026-04-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 1
1 source rowRow 1 · 2026-04-07 · Disposition to issuer · Disposed 25,784 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F2: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.79 · Expires 2026-12-14 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-07 · Disposition to issuer · Disposed 1,500 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.92 · Expires 2027-03-08 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-07 · Disposition to issuer · Disposed 6,816 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.44 · Expires 2028-03-14 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-07 · Disposition to issuer · Disposed 7,551 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.81 · Expires 2029-03-07 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-07 · Disposition to issuer · Disposed 6,523 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.36 · Expires 2030-03-05 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-07 · Disposition to issuer · Disposed 7,322 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.03 · Expires 2031-03-11 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-07 · Disposition to issuer · Disposed 5,055 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.28 · Expires 2032-03-10 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-07 · Disposition to issuer · Disposed 5,293 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.49 · Expires 2033-03-09 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-07 · Disposition to issuer · Disposed 4,210 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.32 · Expires 2034-03-07 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-07 · Disposition to issuer · Disposed 4,536 · Balance 0 F3: For Footnote (3), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.36 · Expires 2035-02-26 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-04-07 · Disposition to issuer · Disposed 5,535 · Balance 0 F3: For Footnote (3), see Remarks below. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration").
F2: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
F3: For Footnote (3), see Remarks below.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2018 Filed Aug 16, 2018 21:10 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 5,000 | $36.89 | $184,450.00 |
DisclosureSEC source: 0001179110-18-010631 · edgar.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,333 F1 · shares: The reporting person purchased these shares in her individual capacity in the open market and not through any directed share or other formal program. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $36.85 to $36.95. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:11 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 4,780 | $0.00 Strike: $49.65 | $0.00 |
DisclosureSEC source: 0001179110-18-008113 · edgar.xml · derivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,780 Underlying: Common Stock · 4,780 shares Expires 2028-06-01 F1 · derivative.exercise_date: Non-qualified stock option grant for service as Director on Company's Board of directors. Options vest in equal installments every three months for the first nine months, with the final installment vesting on the earlier of the date of the 2019 annual shareholders meeting or May 31, 2019. Number of shares pursuant to option are based on $120,000 valuation as of the grant date. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 20:33 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 7,551 | $0.00 Strike: $38.44 | $0.00 |
DisclosureSEC source: 0001127602-18-011839 · form4.xml · derivative · entry 3 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,551 Underlying: Common Stock · 7,551 shares Expires 2028-03-14 F3 · derivative.exercise_date: Options become exercisable on the date of the 2019 Annual Meeting of Stockholders. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 20:33 UTC | HOLOGIC INC HOLX · Entity 12463 | PurchaseCommon Stock | 5,200 | $38.43 | $199,825.60 |
DisclosureSEC source: 0001127602-18-011839 · form4.xml · nonDerivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,297 Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 20:33 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 2,406 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-011839 · form4.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,097 F1 · shares: Represents restricted stock units which vest on the date of the 2019 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| September 14, 2017 Filed Sep 15, 2017 21:05 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | PurchaseCommon Stock | 16,264 | $1.23 | $20,004.72 |
DisclosureSEC source: 0001455244-17-000041 · edgar.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,264 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.22 to $1.24, inclusive. The reporting person undertakes to provide to Ekso Bionics Holdings, Inc., any security holder of Ekso Bionics Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:15 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001455244-17-000014 · edgar.xml · derivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-07-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal monthly installments beginning on the one-month anniversary of the date of grant. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:49 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 15,000 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001179110-17-008551 · edgar.xml · derivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-01 F1 · derivative.exercise_date: Non-qualified stock option grant for service as Director on Company's Board of directors. Options vest in equal installments every three months for the first nine months, with the final installment vesting on the date of the then current annual meeting. Read SEC document |
| March 08, 2017 Filed Mar 9, 2017 21:40 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 6,816 | $0.00 Strike: $41.92 | $0.00 |
DisclosureSEC source: 0001127602-17-011068 · form4.xml · derivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,816 Underlying: Common Stock · 6,816 shares Expires 2027-03-08 F3 · derivative.exercise_date: Options become exercisable on the date of the 2018 Annual Meeting of Stockholders. Read SEC document |
| March 08, 2017 Filed Mar 9, 2017 21:40 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 2,206 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-011068 · form4.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,191 F1 · shares: Represents Restricted Stock Units (RSUs) which vest on the date of the 2018 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: RSUs convert into common stock on a one-for-one basis upon vesting. Read SEC document |
| December 29, 2016 Filed Jan 3, 2017 21:46 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 5,000 | $0.00 Strike: $8.95 | $0.00 |
DisclosureSEC source: 0001179110-17-000088 · edgar.xml · derivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2026-12-29 F1 · derivative.exercise_date: Non-qualified stock option grant for service as Director on Company's Board of directors. Vesting is 100% upon the director's re-election to the Company's Board of Directors at the 2017 Annual Meeting of Shareholders. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 21:30 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $40.79 | $0.00 |
DisclosureSEC source: 0001127602-16-070294 · form4.xml · derivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2026-12-14 F3 · derivative.exercise_date: Options become exercisable on the date of the 2017 Annual Meeting of Stockholders. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 21:30 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 485 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-16-070294 · form4.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485 F1 · shares: Represents Restricted Stock Units (RSUs) which vest on the date of the 2017 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: RSUs convert into common stock on a one-for-one basis upon vesting. Read SEC document |
| October 07, 2016 Filed Oct 14, 2016 19:36 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 13,333 | $7.50 | $99,997.50 |
DisclosureSEC source: 0001179110-16-030715 · edgar.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 F1 · shares: The reporting person purchased these shares in her individual capacity and not through any directed share or other formal program in connection with an underwritten registered public offering of the Company. On October 7, 2016, the trade date for the public offering, the closing sale price reported by NASDAQ was $9.15 per share. The public offering closed on October 13, 2016 and the closing sale price reported by NASDAQ on such date was $8.72 per share. F1 · price: The reporting person purchased these shares in her individual capacity and not through any directed share or other formal program in connection with an underwritten registered public offering of the Company. On October 7, 2016, the trade date for the public offering, the closing sale price reported by NASDAQ was $9.15 per share. The public offering closed on October 13, 2016 and the closing sale price reported by NASDAQ on such date was $8.72 per share. Read SEC document |
| September 16, 2016 Filed Oct 13, 2016 16:10 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 3,750 | $8.57 Strike: $8.57 | $32,137.50 |
DisclosureSEC source: 0001179110-16-030674 · edgar.xml · derivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires 2023-09-16 F2 · derivative.exercise_date: Annual option grant for director of Issuer's Board of Directors, pro-rated for joining Board of Directors during annual period. Option vests as to all shares December 28, 2016 in conformity with vesting for such annual director grants. Read SEC document |
| September 16, 2016 Filed Oct 13, 2016 16:10 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 25,000 | $0.00 Strike: $8.57 | $0.00 |
DisclosureSEC source: 0001179110-16-030674 · edgar.xml · derivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2023-09-16 F1 · derivative.exercise_date: Option grant for joining the Issuer's Board of Directors. Options vest quarterly as to 12.5% of total share amount beginning with the first vesting date on December 16, 2016 and becoming fully vested September 16, 2018 (two years after grant). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.